Back to search

The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC)

Melanie B. Thomas, Romil Chadha, Michiko Iwasaki, K. Y. Glover, James L. Abbruzzese
DOI: 10.1200/jco.2007.25.18_suppl.4567
Journal of Clinical Oncology

Data up to Jan 2025

Published2007
Citations62
References0
Fields
MedicineInternal medicineGastroenterologyOncology

Total Citations Per Year

Abstract

References (0)

No references found

Cited By (0)

Loading...
The combination of bevacizumab (B) and erlotinib (E) shows significant biological… (2007) – Journal of Clinical Oncology | Metascience Observatory Explorer